AXSMAxsome Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $638M
- 66% YoY
- Operating margin
- -26.1%
- 64% YoY
- EBITDA
- −$166M
- 41% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$202M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired15% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear2% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | $50M | $271M | $386M | $638M | 66% |
| Operating income | −$125M | −$180M | −$232M | −$281M | −$167M | 41% |
| Net income | −$130M | −$187M | −$239M | −$287M | −$183M | 36% |
| Operating cash flow | −$108M | −$117M | −$145M | −$128M | −$93M | 27% |
| Capex | $308K | $702K | $582K | $270K | $480K | 78% |
| Stock-based comp | $21M | $38M | $63M | $85M | $94M | 10% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $10M | $34M | 224 | 125 |
| FY2024 | $10M | $10M | 104 | 93 |
| FY2023 | $10M | $10M | 98 | 94 |
| FY2022 | $8M | $28M | 95 | 90 |
| FY2021 | $8M | −$11M | 46 | 100 |